Feb. 12, 2018: 9 a.m. - 10:15 a.m.
As the recently approved, initial CAR-T therapies have shown they can produce dramatic improvements for some closely defined patient populations, the next phase of attention shifts to stretching those immuno-oncology (I-O) findings into additional targets, platforms, and indications. These new approaches include allogenic CAR-T products, T-cell regulators, oncolytic viruses, natural killer (NK) cells, and other I-O technologies. This session will discuss the dynamic opportunities in this space to fight cancer even more effectively.
Moderator: Asthika Goonewardene, Senior Biotechnology Analyst, Bloomberg Intelligence
Samuele Butera, Global Cell & Gene Therapies Business Leader, Novartis
Sadik Kassim, PhD, Vice President, Head of Process and Analytical Development, Mustang Bio
Didier Landais, Global Head of Licensing, Servier
Charles Link, MD, Co-Founder, Chairman, CEO, Chief Scientific Officer, NewLink Genetics
Adelene Q. Perkins. Chair and Chief Executive Officer, Infinity Pharmaceuticals
Tito A. Serafini, PhD, President, Chief Executive Officer, and Co-Founder, Atreca, Inc.